- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03870113
DC Vaccines Targeting HPV16/18 E6/E7 Protein to Regress CINI/CIN2
Clinical Study on the Regress of Cervical Intraepithelial Neoplastic(CIN) 1/CIN2 by Highly Effective DC Vaccines Targeting HPV E6/ E7 Protein
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Cervical cancer is the second most common cause of cancer-related deaths among women worldwide with 10000 new cases each year in China. The high-risk human papillomavirus (HPV) was the major cause of cervical cancer. The oncoproteins E6 and E7 encoded by HPV16 and 18, are consistently expressed in HPV-associated Cervical cancer and are responsible for the cervical cancer malignant progression. Targeting the E6/E7 proteins could be very helpful to regress the CIN 1/2 and block the tumorigenesis.
By this research, we aim to establish the HPV16/18 E6/E7 peptide library which could induce the strong anti-virus immune response and to vaccinate the CIN 1/2 patients with dendritic cell vaccines loaded HPV 16/18 E6/E7 epitopes.
Including:
- To create an effective HPV 16/18 E6/E7 antigen peptide library using NetMHCspan software based on the MHC-I subtype of the Chinese population and screen E6/E7protein peptides with high binding affinity to MHC molecules;
- To develop HPV 16/18 E6/E7- pulsed DC vaccines and evaluate the safety and efficacy of DC vaccines;
- The patients are vaccinated with the HPV16/18 E6/E7- pulsed DC vaccines
- To evaluate the safety and efficacy of DC vaccines loaded with HPV 16/18 E6/E7.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Guangdong
-
Shenzhen, Guangdong, China, 518020
- Shenzhen People's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥18 years ≤ 70 years at the time of informed consent
- HPV type 16/18 positive
- Pathologically confirmed CIN1/2 and no other cervical disease
- adequate organ functions.
Exclusion Criteria:
- Severe allergy to drugs
- Women of child-bearing potential who are pregnant or breast-feeding
- Any form of primary immunodeficiency
- With serious cardiac, cerebrovascular and primary diseases
- With a history of severe mental illness
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vaccinated group
Patients will be vaccinated with autologous mature dendritic cells-loaded with HPV 16/18 E6/E7, DC vaccine will be injected into the adjacent lymph-node 6 times, once a week.
|
Develop highly reactive DC vaccines targeting HPV 16/18 E6/ E7 protein and DC vaccine would be injected to patients once a week, six doses in total.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events [Safety]
Time Frame: 3 months after the last vaccination injection
|
Safety of personalized neoantigen vaccine will be measured by the number of subjects experiencing each type of adverse event.
Adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0.
|
3 months after the last vaccination injection
|
Immunogenicity of neoantigen-primed DC Vaccines
Time Frame: once per three month
|
Immunogenicity of the DC vaccine will be measured to detect changes of neoantigen-specific T cells by flow cytometry.
|
once per three month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate
Time Frame: once per three month
|
Objective Response Rate will be measured by detection of protein expression of HPV E6 / E7and evaluation of CIN phase
|
once per three month
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Hui Qi, M.D., Shen Zhen People's Hospital
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ShenzhenPH BTR-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Intraepithelial Neoplasia
-
Krankenhaus Barmherzige Schwestern LinzMedical University of ViennaCompletedCervical Intraepithelial Neoplasia Grade 1 | Cervical Intraepithelial Neoplasia Grade 2Austria
-
National Cancer Institute (NCI)TerminatedCervical Cancer | Cervical Intraepithelial Neoplasia Grade 2 | Cervical Intraepithelial Neoplasia Grade 3United States
-
Genexine, Inc.CompletedCervical Intraepithelial Neoplasia 3Korea, Republic of
-
Nykode Therapeutics ASATheradex; Vaccibody ASCompletedHigh Grade Cervical Intraepithelial NeoplasiaGermany
-
University of Alabama at BirminghamNational Cancer Institute (NCI)CompletedHigh-grade Cervical Intraepithelial NeoplasiaUnited States
-
National Cancer Institute (NCI)Active, not recruitingCervical Intraepithelial Neoplasia Grade 2/3 | High Grade Cervical Intraepithelial Neoplasia | Cervical Squamous Cell Carcinoma In Situ | Cervical Squamous Intraepithelial Neoplasia 2United States
-
Brookdale University Hospital Medical CenterUnknownCarcinoma in Situ of Uterine Cervix | Cervical Intraepithelial Neoplasias | High Grade Cervical Intraepithelial NeoplasiaUnited States
-
BioLeaders CorporationUnknownCervical Intraepithelial Neoplasia Grade 2/3Korea, Republic of
-
University Medical Centre MariborRecruitingCervical Intraepithelial Neoplasia Grade 2 | DNA MethylationSlovenia
-
Onconix, IncUnknownCervical Cancer | Cervical Intraepithelial Neoplasia III | Cervical Intraepithelial Neoplasia IIUnited States
Clinical Trials on Vaccinated group
-
Zhejiang Provincial Center for Disease Control...China National Biotec Group Company ltdCompletedVaccine Reaction | PolioChina
-
Neuroganics LLCRamos Injury Law FirmRecruitingCOVID-19 | Vaccine Adverse Reaction | Vaccine Reaction | Vasculitis | Neuritis | Thrombocytopenia | Influenza | Corona Virus Infection | Blood Clot | Guillain-Barré | Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use | GWAS | Genetic SequencingUnited States
-
Deborah O'ConnorUniversity of Toronto; Sinai Health SystemActive, not recruitingCOVID-19 Vaccine | BreastmilkCanada
-
Yale UniversityUniversity of California, Berkeley; University of Connecticut; Innovations for... and other collaboratorsCompleted
-
Hospices Civils de LyonCompleted
-
Sinovac Biotech Co., LtdCompleted
-
Shanghai First Maternity and Infant HospitalRecruitingCovid-19 | IgG Antibody | Semen IndexChina
-
Falu HospitalCompletedCervical Cancer | HPVSweden
-
E-MO Biology IncActive, not recruitingSARS-CoV-2United States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...PapiVax Biotech, Inc.RecruitingHPV 16+ Recurrent or Metastatic CancerUnited States